Jubilant Ingrevia Limited
Valuation (77/100) does the heavy lifting; momentum (33/100) is the drag.
Buy zoneJubilant Ingrevia Limited earns a Hold from StocksWizard, with a blended score of 56/100. At ₹658.4 it trades below our blended DCF and relative-multiples fair value of ₹794.63, about 21% upside to that estimate — we read it as undervalued by 21%. On 36.1x trailing earnings it sits cheaper than the Chemicals median of about 41.0x. The price is about 14% below its 52-week high of ₹761.24 and 22% above the low of ₹539.48. Financial health scores 70/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 5/9. The average analyst target of ₹939.5 implies about 43% upside across 6 analysts. It clears 7 of 13 investability checks, with durability 46, valuation 70 and momentum 33 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹635.7.
Analyst views
1-year price
EOD · 2026-09-1452-week range
-13.51% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Hold56Piotroski F-score 5/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Fail: ROE above 15%: 9.2%
- Pass: Low debt (D/E < 0.5): 0.25x
- Pass: Positive free cash flow
- Pass: Revenue growth > 10%: 12%
- Pass: Earnings growing: 16%
- Fail: Net margin ≥ 10%: 6.3%
- Fail: Current ratio > 1.5: 1.29
- Pass: Below our fair value
- Pass: Margin of safety ≥ 20%
- Fail: Above 200-day average
- Fail: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 3.8
- Fail: Piotroski ≥ 7: 5/9
Quarterly results
Annual financials
Shareholding
- Promoter50.9%
- Institutions27.7%
- Public & other21.4%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Lightly leveraged balance sheet.
- Financially solid — Altman Z 3.8.
Opportunities
- Earnings growing (16% YoY).
- Revenue growing (12% YoY).
- Trading in our value buy zone versus sector peers.
- Trades ~21% below our estimated fair value.
Bear case
Weaknesses
- Price below its 200-day moving average (downtrend).
About Jubilant Ingrevia Limited
Jubilant Ingrevia Limited manufactures life science products across three segments: Specialty Chemicals, which includes bio-pyridines, picolines, fine chemicals, agro chemicals, custom development and manufacturing services, and microbial control solutions; Nutrition & Health Solutions; and Chemical Intermediates. The company operates in India, the United States, Europe, China and internationally.
Jubilant Ingrevia Limited — frequently asked questions
Is Jubilant Ingrevia Limited a buy, hold or sell?
StocksWizard currently rates Jubilant Ingrevia Limited (JUBLINGREA) a Hold, based on a blended score of 56/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Jubilant Ingrevia Limited's fair value?
Our blended DCF and relative-valuation model estimates Jubilant Ingrevia Limited's fair value at about ₹794.63, versus a current price of ₹658.4 — roughly 21% upside. On that basis the stock looks undervalued by 21%.
Is Jubilant Ingrevia Limited financially healthy?
Jubilant Ingrevia Limited scores 70/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 5/9.
How has Jubilant Ingrevia Limited's share price performed?
Jubilant Ingrevia Limited is up 2% over three months, and last traded at ₹658.4. Past performance doesn't predict future returns.
More in Chemicals
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.